Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ORTHO/CHIRON HCV 3.0 HEPATITIS ANTIBODY SCREENING TEST COULD DETECT UP TO 150 ADDITIONAL INFECTIOUS UNITS PER YEAR -- FDA CMTE. MEMBERS SUGGEST APPROVAL

This article was originally published in The Gray Sheet

Executive Summary

Use of Ortho and Chiron's jointly developed Ortho HCV 3.0 ELISA hepatitis C virus antibody screening test could lead to the detection among voluntary donors of up to 150 more infectious units per year than are identified by screening with the firms' currently available HCV 2.0 test, according to data presented by Ortho at a March 21 meeting of FDA's Blood Products Advisory Committee in Bethesda, Maryland.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005718

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel